Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 7/20 | 0.81 |
| ▸ | HTR1B | P28222 | 7/20 | 0.70 |
| ▸ | HTR1A | P08908 | 6/20 | 0.70 |
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | HTR1F | P30939 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HTR5A | P47898 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630353 | 1.00 | HTR1D (0.81) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL23083092 | 0.93 | HTR1D (0.78) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL27084763 | 0.90 | HTR1D (0.86) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL30630375 | 0.90 | HTR1D (0.77) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL30630423 | 0.90 | HTR1D (0.66) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL24243772 | 0.90 | HTR1D (0.66) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL23083090 | 0.90 | HTR1D (0.77) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL30630492 | 0.90 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL23069154 | 0.90 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL27085100 | 0.89 | HTR1B (0.73) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12171771-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | disclosed |
| US-20240285608-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1D 53/4885HTR1B 20/4885HTR1A 23/4885 |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 13/4885HTR1B 1/4885HTR1A 12/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | HTR1D 14/4885HTR1B 1/4885HTR1A 15/4885 |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | HTR6, HTR4, CNR1 | HTR1D 13/4885HTR1B 9/4885HTR1A 8/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-12171771-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 15/4885HTR1B 1/4885HTR1A 13/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1D 7/4885HTR1B 1/4885HTR1A 11/4885 |
| US-20240285608-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | HTR1D 14/4885HTR1B 1/4885HTR1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.